Influenza and Other Respiratory Viruses最新文献

{"title":"The Potential for Twice-Annual Influenza Vaccination to Reduce Disease Burden","authors":"Shuyi Zhong,&nbsp;Mark G. Thompson,&nbsp;Benjamin J. Cowling","doi":"10.1111/irv.70052","DOIUrl":"https://doi.org/10.1111/irv.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza vaccination is recommended annually based on the evolving nature of influenza viruses and the waning of vaccine-induced immunity. The timing of vaccination is usually before the winter influenza season in most temperate locations, where the seasonality is clear and influenza activities on average last no longer than 6 months. However, many tropical and subtropical areas have year-round influenza activity and multiple epidemics within 1 year, against which annual influenza vaccination may not offer sufficient protection at the individual level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>A twice-annual vaccination program could utilize standard inactivated influenza vaccines or enhanced influenza vaccines. Here, we discuss three reasons to consider twice-annual vaccination as a strategy to improve protection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>The first, mentioned above, is that some locations experience prolonged or year-round influenza activity. The second reason is based on the observation that vaccine effectiveness significantly declines about 6 months after vaccination particularly for A(H3N2) strains, and therefore, vaccination twice a year might be beneficial to maintain a higher level of immunity in the second half of each year. The third reason is to allow for receipt of the most updated vaccine strains, given that these are updated twice each year by the World Health Organization. We also discuss three potential barriers or challenges. The first potential challenge is knowledge gaps, because there are very few existing studies that used twice-annual vaccination. The second potential barrier is a concern over whether more frequent vaccination would lead to reduced immunogenicity or reduced clinical protection in the longer term. The third relates to concerns about cost or feasibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We discuss these issues and recommend comparative assessment of the incremental benefits and cost of twice-annual vaccination versus annual vaccination, as well as other vaccination strategies aiming to reduce influenza disease burden particularly in tropical and subtropical locations where there can be year-round influenza activity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study","authors":"Bronke Boudewijns,&nbsp;Saverio Caini,&nbsp;Marco Del Riccio,&nbsp;Marta C. Nunes,&nbsp;Sandra S. Chaves,&nbsp;Melissa K. Andrew,&nbsp;Justin R. Ortiz,&nbsp;Oana Săndulescu,&nbsp;Joseph S. Bresee,&nbsp;Elena Burtseva,&nbsp;Daouda Coulibaly,&nbsp;Daria M. Danilenko,&nbsp;Kirill Stolyarov,&nbsp;Anca C. Drăgănescu,&nbsp;Mine Durusu Tanriover,&nbsp;Heloisa I. G. Giamberardino,&nbsp;Parvaiz A. Koul,&nbsp;F. Xavier Lopez-Labrador,&nbsp;Shelly A. McNeil,&nbsp;Ainara Mira-Iglesias,&nbsp;Alejandro Orrico-Sanchez,&nbsp;Nancy A. Otieno,&nbsp;Jorim Ayugi,&nbsp;Sonia M. Raboni,&nbsp;Peter Spreeuwenberg","doi":"10.1111/irv.70085","DOIUrl":"https://doi.org/10.1111/irv.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to establish a Severity Scale for influenza and other acute respiratory infections (ARI), requiring hospitalization, for surveillance and research purposes (the SevScale). Such a scale could aid the interpretation of data gathered from disparate settings. This could facilitate pooled analyses linking viral genetic sequencing data to clinical severity, bringing insights to inform influenza surveillance and the vaccine strain selection process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used a subset of data from the Global Influenza Hospital Surveillance Network database, including data from different geographical areas and income levels. To quantify the underlying concept of severity, an item response model was developed using 16 indicators of severity related to the hospital stay. Each patient in the dataset was assigned a Severity Score and a Severity Category (low, medium, or high severity). Finally, we compared the model scores across different subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 9 countries were included, covering between 4 and 11 seasons from 2012 to 2022, with a total of 96,190 ARI hospitalizations. Not for all severity indicators data were available for all included seasons. Subgroups with a high percentage of patients in the high Severity Category included influenza A(H1N1)pdm09, age ≥ 50, lower-middle income countries, and admission since the start of the COVID-19 pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The initial model successfully highlighted severity disparities across patient subgroups. Repeating this exercise with new, more complete data would allow recalibration and validation of the current model. The SevScale proved to be a promising method to define severity for influenza vaccine strain selection, surveillance, and research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature","authors":"Litjen Tan,&nbsp;L.J,&nbsp;Dana Trevas,&nbsp;Ann R. Falsey","doi":"10.1111/irv.70090","DOIUrl":"https://doi.org/10.1111/irv.70090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Coadministration of vaccines in children is a long-standing practice that has proven to be safe and effective in improving the efficiency of vaccine administration, thereby increasing immunization coverage rates. As the number of vaccines routinely recommended for adults increases, and with limited opportunities for adults to have preventive health touchpoints with providers, adult vaccine coadministration should be considered as a routine practice to improve vaccination coverage rates and public health. A review of existing literature was conducted to examine the potential reactogenicity and impact on effectiveness when co-administering vaccines to adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Medline was searched for research articles with the search term “influenza vaccine” or “vaccination,” combined with the search terms “simultaneous,” “concomitant,” “concurrent,” and “combination.” Another search of Medline was conducted on the search term “influenza vaccine” or “vaccination” combined with the following individual search terms: “RSV,” “COVID,” and “Tdap.” The references of extracted articles were also examined for potential other relevant articles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusions</h3>\u0000 \u0000 <p>Adult vaccine coadministration is safe for all the combinations we assessed. Most adverse events (AEs) were generally mild to moderate and of short duration. Some studies showed slightly more reactogenicity with coadministration but few or no serious AEs or safety signals. Nearly every study confirmed that coadministration had no significant effect on immune response for either vaccine. The benefits of vaccine coadministration outweigh the risks. It increases convenience for vaccinees, reduces the number of missed opportunities to vaccinate, and contributes to efficient use of healthcare resources.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shifts in Respiratory Virus Epidemiology on Reunion Island From 2017 to 2023: Impact of COVID-19 Pandemic and Non-Pharmaceutical Interventions","authors":"Nicolas M'nemosyme,&nbsp;Etienne Frumence,&nbsp;Laurent Souply,&nbsp;Diana Heaugwane,&nbsp;Nicolas Traversier,&nbsp;Alizé Mercier,&nbsp;Jamel Daoudi,&nbsp;Jean-Sébastien Casalegno,&nbsp;Martine Valette,&nbsp;Marie-Pierre Moiton,&nbsp;Rodolphe Manaquin,&nbsp;Etienne Darieux,&nbsp;Raphaëlle Sarton,&nbsp;Anaïs Grimal,&nbsp;Fabian Thouillot,&nbsp;Xavier Deparis,&nbsp;Bruno Lina,&nbsp;Marie-Christine Jaffar-Bandjee","doi":"10.1111/irv.70075","DOIUrl":"https://doi.org/10.1111/irv.70075","url":null,"abstract":"&lt;p&gt;The emergence of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in late December 2019 in Wuhan, China, has had a profound impact worldwide [&lt;span&gt;1, 2&lt;/span&gt;]. Reunion Island, situated in the southwest of the Indian Ocean and spanning 2500 km&lt;sup&gt;2&lt;/sup&gt; as a French overseas department, is inhabited by around 885,700 people, primarily residing along the coastal areas. On this island, the first case of COVID-19 was reported on March 11, 2020, at the University Hospital Center (UHC) of La Reunion, in a group of travelers returning from a cruise [&lt;span&gt;3&lt;/span&gt;]. Given the lack of available treatments to combat the infection during that period, the government implemented a comprehensive array of public health measures on Reunion Island, similar to those in metropolitan France, in an effort to control the spread of the virus. These measures, referred to as non-pharmaceutical interventions (NPIs), included a strict lockdown period and the closure of all schools and childcare centers on the island from March 17, 2020, to May 11, 2020. Subsequently, in August 2020, control measures were formally introduced on the island, encompassing social distancing and mandatory mask-wearing in public. Starting in July 2020, several SARS-CoV-2 screening campaigns were launched across all cities on the island, aiming to test all travelers entering and leaving the island, as well as all hospital admissions.&lt;/p&gt;&lt;p&gt;These NPIs were implemented both to reduce the transmission of the virus and to prevent the healthcare system from exceeding its capacity of intensive care beds [&lt;span&gt;4&lt;/span&gt;]. Thanks to these measures, Reunion Island registered only 9037 cases and 42 deaths during the initial year of the COVID-19 pandemic, managing to remain relatively unscathed [&lt;span&gt;5&lt;/span&gt;]. The vaccination campaign began on January 15, 2021, and in the subsequent months, a range of new NPIs, including lockdowns and curfews, were introduced. Nevertheless, the island encountered numerous successive waves of infection caused by different variants of SARS-CoV-2 (such as Beta, Delta, and Omicron variants) [&lt;span&gt;6&lt;/span&gt;]. This led to over 82,796 reported cases in 2021 and a surge to more than 420,850 cases in 2022, according to regional public health authority statistics [&lt;span&gt;6, 7&lt;/span&gt;]. The year 2023, on the other hand, was a year of low SARS-CoV-2 circulation on the island [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;It has been reported that the combination of SARS-CoV-2 circulation and NPIs across the world has had a significant impact on the circulation of other respiratory viruses [&lt;span&gt;9-14&lt;/span&gt;]. Notably, a global decline in influenza cases and a shift in the seasonal transmission pattern of respiratory syncytial virus (RSV) were evident worldwide. In mainland France, no influenza outbreaks were reported for the 2020–2021 season following the implementation of NPIs, while the RSV bronchiolitis outbreak in children was delayed ","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess All-Cause Mortality by Age and Gender During the COVID-19 Pandemic in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina: 2020–2022","authors":"Šeila Cilović-Lagarija,&nbsp;Johanna Thea Mølgaard Rantzau,&nbsp;Siniša Skočibušić,&nbsp;Sanjin Musa,&nbsp;Armin Sprečo,&nbsp;Amna Isaković,&nbsp;Mirza Palo,&nbsp;Faris Dizdar,&nbsp;Hidajeta Čolović,&nbsp;Veronica Ivey Sawin,&nbsp;Jens Nielsen,&nbsp;Pernille Jorgensen","doi":"10.1111/irv.70086","DOIUrl":"https://doi.org/10.1111/irv.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>COVID-19 has had a profound impact on global mortality and morbidity, yet only a fraction of deaths was confirmed and reported. We estimated all-cause excess mortality from 1 January 2020 to 31 December 2022 in the Federation of Bosnia and Herzegovina (FBiH) to assess the true magnitude of the pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data for this analysis was sourced from the FBiH mortality register and supplemented with population statistics and official COVID-19 death counts (i.e., cases where COVID-19 was registered as the cause of death). Using a Poisson model, all-cause excess number of deaths and rates per 100,000 person-years, adjusted for registration delays and stratified by age and gender, were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>FBiH experienced three periods of excess all-cause mortality throughout the first 3 years of the pandemic, with a total of 12,000 excess deaths, highest among adults 45–74 years and males. No excess mortality was observed in children &lt;15 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The true mortality impact of COVID-19 in FBiH was substantially higher than the reported deaths, including among younger adults. Strengthening civil registration and vital statistics, including establishment of all-cause mortality surveillance, is essential for improved monitoring of future pandemics and other important public health events. A detailed review of the direct and indirect effects of COVID-19 on mortality should be conducted to identify areas that require more resources, improve health provision and inform mitigation efforts in future pandemics to save lives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe”","authors":"","doi":"10.1111/irv.70087","DOIUrl":"https://doi.org/10.1111/irv.70087","url":null,"abstract":"<p>\u0000 <span>Heemskerk, S.</span>, <span>Baliatsas, C.</span>, <span>Stelma, F.</span>, <span>Nair, H.</span>, <span>Paget, J.</span>, &amp; <span>Spreeuwenberg, P.</span> <span>Assessing the Impact of Non-Pharmaceutical Interventions During the COVID-19 Pandemic on RSV Seasonality in Europe</span>. <i>Influenza and Other Respiratory Viruses.</i> <span>2025</span>; <span>19</span>(<span>1</span>), e70066.\u0000 </p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022)”","authors":"","doi":"10.1111/irv.70084","DOIUrl":"https://doi.org/10.1111/irv.70084","url":null,"abstract":"<p>\u0000 <span>Conte, D.D.</span>, <span>Watanabe, R.A.S.</span>, <span>Chaves, A.P.C.</span>, <span>Alberto-Lei, F.</span>, <span>Perosa, A.H.S.</span>, <span>Barbosa, G.</span> and <span>Bellei, N.</span> (<span>2024</span>), <span>Impact of Variants, Epidemiological Trends, and Comorbidities on Hospitalization Rates of Unvaccinated Children in Brazil: A Retrospective Study (2020–2022)</span>. <i>Influenza Other Respi Viruses</i>, <span>18</span>: e70011, https://doi.org/10.1111/irv.70011.\u0000 </p><p>In the article, the funding information was incomplete.</p><p>The funding details read:</p><p>This study was supported by FINEP/UFMG/REITORIA/PRPQ (29334)</p><p>The funding details should read:</p><p>This study was supported by FINEP/UFMG/EDITORIAL/PRPQ (29334) and São Paulo State Research Support Foundation (2023/07391-7).</p><p>The online version of the article has been corrected.</p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age”","authors":"","doi":"10.1111/irv.70088","DOIUrl":"https://doi.org/10.1111/irv.70088","url":null,"abstract":"<p>\u0000 <span>Curran, D</span>, <span>Matthews, S</span>, <span>Cabrera, ES</span>, et al., <span>The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of Respiratory Syncytial Virus-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age</span>. <i>Influenza Other Respi Viruses.</i> <span>2024</span>; <span>18</span>(<span>2</span>):e13236.\u0000 </p><p>In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below.</p><p>Desmond Curran ¹ |Sean Matthews ²|Eliazar Sabater Cabrera ¹ |Silvia Narejos Pérez ³|Lina Pérez Breva ⁴|Mika Rämet ⁵|Laura Helman ⁶|Dae Won Park ⁷|Tino F. Schwarz ⁸|Isabel Maria Galan Melendez ⁹|Axel Schaefer ¹⁰|Nathalie Roy ¹¹|Brigitte Stephan ¹²|Daniel Molnar ¹ |Lusine Kostanyan ¹ |John H. Powers III ¹³|Veronica Hulstrøm ¹|Members of the AReSVi-006 Study Group</p><p>¹GSK, Wavre, Belgium</p><p>² Freelance c/o GSK, Wavre, Belgium</p><p>³ CAP Centelles, Barcelona, Spain</p><p>⁴ Vaccine Research, FISABIO-Public Health, Valencia, Spain</p><p>⁵ Finnish Vaccine Research, Tampere, Finland</p><p>⁶ MOC Research, Mishawaka, Indiana, USA</p><p>⁷ Korea University Ansan Hospital, Ansan, Republic of Korea</p><p>⁸ Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany</p><p>⁹ Hospital Universitario Fundacion Alcorcon, Madrid, Spain</p><p>¹⁰ Medizentrum Essen Borbeck, Essen, Germany</p><p>¹¹ Medicor Research, Greater Sudbury, Canada</p><p>¹² SGS proDERM, Schenefeld, Germany</p><p>¹³ Department of Clinical Medicine, George Washington University School of Medicine &amp; Health Sciences, Washington, District of Columbia, USA</p><p>We apologize for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143475346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Respiratory Viruses Other Than SARS-CoV-2 in a Large Hospital Laboratory in Rome, Italy, During the Seasons 2016–2017 to 2022–2023","authors":"Flora Marzia Liotti,&nbsp;Simona Marchetti,&nbsp;Sara D'Onghia,&nbsp;Maurizio Sanguinetti,&nbsp;Rosaria Santangelo,&nbsp;Brunella Posteraro","doi":"10.1111/irv.70079","DOIUrl":"https://doi.org/10.1111/irv.70079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Respiratory viruses are major contributors to morbidity and mortality worldwide, with their circulation influenced by seasonal patterns and pandemic-related interventions. This study analyzed detection trends of non-SARS-CoV-2 respiratory viruses in a large Italian hospital over a 7-year period, focusing on variations across COVID-19–related periods and patient age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed multiplex PCR-based laboratory results of 8836 nasopharyngeal samples collected between September 2016 and August 2023. Viral detection rates were stratified by season, COVID-19–related periods (pre-pandemic, pandemic, post-pandemic), and age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 8836 nasopharyngeal samples analyzed, 2795 (31.6%) tested positive for at least one respiratory virus. Rhinovirus/enterovirus (RV/EV) was the most frequently detected virus (37.6%), followed by influenza A virus (IAV, 17.9%) and respiratory syncytial virus (RSV, 17.2%). The 2020–2021 season had the lowest positivity rate (<i>p</i> &lt; 0.001), with marked declines in IAV and RSV detections, likely because of COVID-19 mitigation measures. Conversely, detections of RV/EV and human coronaviruses increased. Postpandemic data suggested a return to prepandemic patterns, though overall positivity rates remained altered. Age-stratified analysis revealed RSV predominance in infants (<i>p</i> &lt; 0.001), emphasizing its clinical relevance in pediatric populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings highlight the dynamic nature of respiratory virus epidemiology and the persistent impact of the COVID-19 pandemic on viral circulation. Continuous surveillance and adaptive public health strategies are essential for managing future outbreaks and mitigating the burden of respiratory viral infections.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Analysis of Human Respiratory Syncytial Virus Group B Strains Isolated in Kenya Before and During the Emergence of Pandemic Influenza A/H1N1","authors":"Julia Wangui,&nbsp;George Gachara,&nbsp;Victor Mobegi,&nbsp;Charles Agoti,&nbsp;James Otieno,&nbsp;Silvanos Opanda,&nbsp;Benjamin Opot,&nbsp;Joseph N. Ngeranwa,&nbsp;Regina Njeru,&nbsp;Wallace Bulimo","doi":"10.1111/irv.70082","DOIUrl":"https://doi.org/10.1111/irv.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We conducted a retrospective study to explore molecular insights into human respiratory syncytial virus (HRSV) group B strains among patients attending outpatient clinics at government medical facilities both prior and during the onset of Influenza A/H1N1/2009 pandemic outbreak.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We screened 2300 nasopharyngeal swabs using multiplex real time reverse transcriptase polymerase chain reaction. We amplified a segment of the first and second hypervariable regions, as well as the conserved portion of the third domain of the G-gene using HRSV-B specific primers, sequenced by Sanger di-deoxy chain termination method and thereafter analyzed the sequences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We characterized the circulating strains into three known genotypes: SAB4 (1.4%), BA7 (1.4%), and multiple variants of BA9 (97.2%). The majority of BA9 viruses were uniquely Kenyan with only 4% aligning with BA9 lineages found elsewhere. The mean evolutionary rate of the HRSV-B was estimated to be 3.08 × 10⁻³ substitutions per site per year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings indicate that the circulating HRSV-B viruses in Kenya underwent a slower evolution during the period of 2007–2010. Additionally, our findings reveal the existence of a unique lineage as well as new variants that have not been reported elsewhere to date.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}